Institute of Rocket Force Medicine, State Key Laboratory of Trauma, Burns and Combined Injury, College of Preventive Medicine, Third Military Medical University (Army Medical University), Chongqing 400038, China.
Department of Hematology, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing 400037, China.
Sci Adv. 2021 Jan 1;7(1). doi: 10.1126/sciadv.abb6104. Print 2021 Jan.
Acute myeloid leukemia (AML) is a deadly hematological malignancy with frequent disease relapse. The biggest challenge for AML therapy is the lack of methods to target and kill the heterogeneous leukemia cells, which lead to disease relapse. Here, we describe a near-infrared (NIR) fluorescent dye, IR-26, which preferentially accumulates in the mitochondria of AML cells, depending on the hyperactive glycolysis of malignant cell, and simultaneously impairs oxidative phosphorylation (OXPHOS) to exert targeted therapeutic effects for AML cells. In particular, IR-26 also exhibits potential for real-time monitoring of AML cells with an in vivo flow cytometry (IVFC) system. Therefore, IR-26 represents a novel all-in-one agent for the integration of AML targeting, detection, and therapy, which may help to monitor disease progression and treatment responses, prevent unnecessary delays in administering upfront therapy, and improve therapeutic efficiency to the residual AML cells, which are responsible for disease relapse.
急性髓系白血病（AML）是一种致命的血液系统恶性肿瘤，常伴有疾病复发。AML 治疗的最大挑战是缺乏靶向和杀伤异质性白血病细胞的方法，这导致疾病复发。在这里，我们描述了一种近红外（NIR）荧光染料 IR-26，它依赖于恶性细胞的过度活跃糖酵解，优先积聚在 AML 细胞的线粒体中，同时损害氧化磷酸化（OXPHOS），以发挥针对 AML 细胞的靶向治疗作用。特别是，IR-26 还可以通过体内流式细胞术（IVFC）系统实时监测 AML 细胞。因此，IR-26 代表了一种新型的 AML 靶向、检测和治疗一体化的试剂，它可能有助于监测疾病进展和治疗反应，防止不必要地延迟进行一线治疗，并提高对负责疾病复发的残留 AML 细胞的治疗效率。
